Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome.

ABSTRACT:

Background

The gut microbiota influences many aspects of host physiology, including immune regulation, and is predictive of outcomes in cancer patients. However, whether conventional myelosuppressive chemotherapy affects the gut microbiota in humans with non-haematological malignancy, independent of antibiotic exposure, is unknown.

Methods

Faecal samples from 19 participants with non-haematological malignancy, who were receiving conventional chemotherapy regimens but not antibiotics, were examined prior to chemotherapy, 7-12 days after chemotherapy, and at the end of the first cycle of treatment. Gut microbiota diversity and composition was determined by 16S rRNA gene amplicon sequencing.

Results

Compared to pre-chemotherapy samples, samples collected 7-12 days follow

SUBMITTER: Papanicolas LE 

PROVIDER: S-EPMC8141218 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature